Page 28 - Recursion Pharmaceuticals News Today

/PRNewswire/ -- The "Desmoid Tumors - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.coms offering. This report provides...

Biopharma companies are harnessing AI tools for multiple aspects of drug development such as identifying drug development targets, modeling a drug's effect on the body, and more.

It's just starting to dip its toes into the biopharma waters.

Healthcare stocks have struggled to gain traction this year, but a select few smaller companies are defying the trend by leveraging the power of artificial…

A few smaller biotech companies are defying the industry trend by leveraging the power of artificial intelligence.

News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. Nasdaq: NVDA into AI-powered drug discovery company Recursion…

Health-care companies ticked down amid concerns about growth in the sector. Thermo Fisher Scientific slid after the maker of scientific instruments cut its...

Health-care companies ticked down amid concerns about growth in the sector. Thermo Fisher Scientific slid after the maker of scientific instruments cut its forecasts for earnings and sales,...

SALT LAKE CITY, July 26, 2023 -- Recursion , a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today launched Valence Labs at the International Conference...

Nikko Asset Management Americas Inc. boosted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 10.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 501,977 shares of the company’s stock after buying an additional 47,455 shares during the […]